
    
      The main objective of the study is to demonstrate that in patients considered to be at high
      risk for PE (from the first-trimester screening) and with sFlt-1/PlGF ratio <38, between 24+0
      and 27+6 weeks, the incidence of PE, after cessation of the treatment with ASA, will not be
      superior to that of the control group.
    
  